Chiropractic care for hypertension: Review of the literature and study of biological and genetic bases

Stephanie GB Sullivan1, Stefano Paolacci2, Aysha Karim Kiani3, Matteo Bertelli2,3,4
1 Office for Senior Health and Wellness, Dr. Sid E. Williams Center for Chiropractic Research, Life University, Marietta, GA, USA; 2 MAGI'S LAB, Rovereto (TN), Italy; 3 MAGI EUREGIO, Bolzano, Italy; 4 EBTNA-LAB, Rovereto (TN), Italy

Abstract. Background and aim: Hypertension is a multifactorial condition that is among the leading causes of mortality worldwide. Regulation of blood pressure greatly depends upon the activity of the autonomic nervous system. Alterations in the autonomic nervous system can lead to hypertension. In addition to nervous system control and individual physiologic state, various genes can directly influence autonomic responses. The complexity of blood pressure control is reflected in the 20-30% of individuals resistant to traditional pharmacological treatment, this indicates the need for alternative interventions. This article provides an integrative review and discussion of the key neurophysiologic and genetic factors that contribute to blood pressure regulation, the autonomic nervous system (ANS) and manual therapy literature, and the manual therapy and blood pressure literature.

Methods: To assess the effects of chiropractic on the management of hypertension we searched articles published from 1980 to 2019 in PubMed, the Index to Chiropractic Literature and CINAHL, using the keywords: chiropractic, spinal manipulation, hypertension, and blood pressure.

Results: We found 38 original studies that analyzed the effect of chiropractic therapy on hypertension. Of these studies, 10 were case reports and the statistical significance of the effects of chiropractic on blood pressure was not evaluated on these articles, so we focused on the remaining 28 articles.

Conclusions: The results of the review relative to chiropractic care were promising, but often contradictory, suggesting more research should be done. In consideration of the complexity of ANS blood pressure control, an evaluation of patient presenting physiologic and genetic characteristics is recommended and could provide valuable insight relative to the likelihood of patient blood pressure related responsiveness to care (www.actabiomedica.it)

Key words: hypertension, autonomic nervous system, spinal manipulative therapy, chiropractic manipulative therapy, sympathetic response, parasympathetic response

Introduction

Hypertension (high blood pressure) is a common multifactorial disorder that results in high morbidity and mortality around the world (1). According to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, hypertension is defined as systolic blood pressure of 140 mmHg or above with diastolic blood pressure of 90 mmHg or above (2).

Although recent advancements enable us to better understand the etiology of hypertension and provide new treatment options, the prevalence of hypertension is increasing. Globally, almost 26% of the adult population is experiencing hypertension at present, and according to an estimation by Kearney et al, the prevalence will increase to 29% by 2025 (3). Adding to the complexity of the challenge, almost 90% of hypertensive cases are of essential (primary, with an unknown etiology) hypertension, which is the 13th significant cause of mortality in the United States (4).

As a multifactorial condition, there are a number of risk factors associated with the development of primary hypertension. Genetics, for example, have been
shown to play a major role in the onset of hypertension, along with other factors such as sex, age, weight, diet, stress, physical activity, hormones and cigarettes smoking (4). However, the effect of genetics, weight, diet or other risk factors as singular causes of hypertension is less supported (5). Emerging research suggests that the etiology or foundational susceptibility of an individual to the development of hypertension may be associated with dysfunctional regulation of the autonomic nervous system (ANS), particularly to the abnormal activation of parasympathetic and sympathetic systems (6-8). A review by Grassi showed that an increased sympathetic drive may serve as an amplifier or determinate of elevated blood pressure and its associated effects (9). Interestingly, a number of genetic variations associated with high blood pressure are also involved in changes to sympathetic control (10-13). The association between high blood pressure and aberrant autonomic control is important because it provides a gateway for therapeutic intervention, especially because many pharmaceutical approaches directly target or mimic autonomic nervous system responses (14).

There are two main challenges to pharmacotherapy for hypertension, therapeutic resistance and medication side effects (15-18). Resistant hypertension - defined as individuals who fail to reach their target blood pressure despite being on three concurrent medications at prescriptive doses, with one medication being a diuretic – is present in 20-30% of hypertensive individuals (15,19-20). Further, this population presents with greater risk of health complications and mortality (15,19,21-22). Relative to medication side effects, they range from mild, such as dizziness, headaches, electrolyte imbalance, and cough to more serious events including erythema multiforme major, heart palpitations, increased creatinine, vasovagal syncope, and renal impairment (16-18). Given the rise in hypertensive cases and the challenges to pharmacotherapy, alternative interventions with limited risk should be explored, and further examination of therapies such as chiropractic - shown to influence the ANS - could be a likely candidate (2,16-18,23-25).

Chiropractic care as a therapeutic intervention for blood pressure regulation is not a new concept, although the research examining blood pressure changes following care does not consistently provide support (26-29). This inconsistency could be the result of the complexity of neurophysiologic control of blood pressure regulation and/or genetic variability. The aim of this article was not to conduct a formal systematic review, but to discuss the literature from an integrative perspective and highlight the need for additional outcome assessments (e.g. genetic predisposition), following three topics: key neurophysiologic and genetic factors that contribute to blood pressure regulation, the ANS and manual therapy literature, and the manual therapy and blood pressure literature.

Regulation of blood pressure

Arterial blood pressure is primarily regulated by the ANS, which comprises the parasympathetic and sympathetic nervous systems (6,30). These two systems are counterbalanced and constantly regulate and control blood pressure through receptor-based feedback loops (30). Although it is acknowledged that cortical control of blood pressure is a factor, as evidenced by elevated blood pressure while in a doctor’s office (white coat syndrome) and meditation-based blood pressure control, this article will focus on two receptor-based ANS control mechanisms, the baroreceptor response and the renin-angiotensin-aldosterone system (RAAS) (31-34).

Autonomic Nervous System Regulation

Alterations of ANS activity have a direct role in the onset and development of human hypertension (6,30,35). The increase of sympathetic nervous system activity and the reduction of vagal cardiac tone are associated with the onset and persistence of hypertension (6,36).

Interestingly, both sympathetic and parasympathetic divisions of the ANS might present with abnormal activity in individuals with higher hypertension risk, even before the onset of any clinical signs (30,37,38). Patients in the early stages of hypertension have amplified sympathetic and decreased cardiac vagal (parasympathetic) activities (30,37,39). A review by Mancia and Grassi showed marked alterations in ANS control in prehypertensive, early hypertensive,
and established hypertensive states (30). Decrease in cardiac parasympathetic nervous system activity, estimated by the analysis of heart rate variability, has also been shown to increase mortality rate (40). Further, according to animal studies, alterations of the sympathetic system cause observed inter-individual variability of blood pressure (35). This is confirmed in adult rats, spontaneously hypertensive, that show reduction in cardiac parasympathetic nervous activity, accompanied with increased sympathetic nerve activity and elevated noradrenaline release (41).

**Baroreflex**

The baroreflex has the ability to buffer the acute changes of arterial pressure (42). The buffering of blood pressure is usually mediated by the parasympathetic and sympathetic regulated heart rate and the sympathetic vasomotor tone modulation (43). The heart rate and the sympathetic nervous system activity are regulated by cardiovascular baroreceptors.

Baroreceptors are mechanoreceptors that increase action potential firing in response to the widening and stretching of the blood vessels (44). The acute changes of blood pressure are regulated by the baroreceptors located in the blood vessels and heart, in particular the high-pressure receptors located in the aortic arch and carotid sinuses (44,45). Baroreceptor activation during elevated blood pressure efficiently inhibits the response of efferent sympathetic nerves and increases the efferent vagal activation on the SA node of the heart. This vagally mediated response leads to release of acetylcholine and inhibition of the SA node – decreasing the heart rate (44,45). Concurrently, the sympathetic mediated norepinephrine release on the SA node is diminished, further decreasing the SA mediated heart rate. As an additional consequence of diminished sympathetic outflow, sympathetic vasomotor tone is decreased, allowing vascular dilation within the venous and arterial systems. The decreased vasomotor tone decreases total peripheral resistance and alters end diastolic and systolic volumes, leading to a decrease in blood pressure (44,45).

The sympathetic and parasympathetic responses are in reverse when stretch on the mechanoreceptors is diminished, as in the case of low blood volume or blood pooling in response to gravity-dependent positional changes (46). The baroreceptor reflexes provide immediate, acute responses to changes in blood pressure or volume. Subsequently, the efferent activities of the sympathetic and parasympathetic nervous systems are readily adjusted to stabilize the blood pressure. Baroreflex afferents are also known to regulate the release of vasopressin from the hypothalamus, which is considered a backup mechanism for the stabilization of blood pressure (43).

Functional loss of the afferent baroreflex leads to baroreflex failure, characterized by unstable arterial hypertension (46). Alternatively, the functional loss of the efferent baroreflex causes autonomic failure linked with intense orthostatic hypotension (46). Although the baroreceptor response is classically adapted for acute homeostatic control, failure or adaptation of the responses can have implications in chronic blood pressure regulation (46,47). In humans, essential hypertension is associated with impaired regulation of heart rate and sympathetically mediated vasomotor tone (30,37,43).

To evaluate the effects of baroreflex failure, the degree of response of the target organs - especially the kidneys - towards the reset of baroreflex control of sympathetic nervous activity helps to establish the levels of the long-term blood pressure and progression of hypertension (43). The changes in sympathetic nervous activity of the kidney, mediated by the baroreflex, might affect the renin-angiotensin-aldosterone system (RAAS) and might also play a role in long-term changes of mean arterial blood pressure through the regulation of humoral factor levels that are active in autonomic regulation (42).

Similar to other mechanoreceptors, such as those in the skin that allow desensitization to clothing or watches, baroreceptor resetting occurs. Baroreceptor resetting might contribute to the development of hypertensive states (48,49). The normalization of baroreceptor sensitivity and the re-establishment of the baroreceptor pressure threshold is considered a promising therapeutic target for blood pressure control. Patients could possibly improve their blood pressure control by the use of novel therapeutic options that restore baroreceptor function and ANS responsiveness (42,48,49).
The renin-angiotensin-aldosterone system (RAAS) by interacting with the autonomic nervous system regulates the blood pressure (50). This system comprises several hormones that increase blood volume and peripheral resistance. The RAAS is activated in response to decreased blood volume, increased sodium, or activation of the sympathetic nervous system, which initiates renin synthesis and release by the juxtaglomerular cells (32). Renin exerts its activity by entering the blood and interacting with angiotensinogen, produced by the liver. Then, renin converts the angiotensinogen into angiotensin I. Subsequently angiotensin I moves to the pulmonary vessels where the angiotensin-converted enzyme (ACE), produced by the endothelium, is converted into angiotensin II. While the lung endothelial tissue is considered the primary converter of angiotensin I to angiotensin II, it should be noted that ACE is produced and can exert effects within other tissues of the body, including the brain, kidneys, and cardiac tissue (51-54). This complicates pharmacologic based therapies such as ACE inhibitors (51,52).

Angiotensin II influences blood pressure through several different pathways. To increase blood volume, resorption and retention of water is increased through sodium resorption in the kidneys. This is accomplished in the proximal tubule of the kidney by angiotensin II and through angiotensin II effects on the zona glomerulosa of the adrenal glands. This leads to release of aldosterone from the adrenal glands, which acts on the late distal tubule and collecting duct of the kidney nephron (55). Additionally, angiotensin II receptors on the hypothalamus increase the sense of thirst, prompting the individual to take in more fluids, increasing blood volume further. Through increased fluid volume, blood pressure rises (55,56).

Angiotensin II also activates and works in concert with the sympathetic nervous system to cause vasoconstriction. This is accomplished through angiotensin II receptors directly on blood vessels and stimulation of post-ganglionic sympathetic neuron release of norepinephrine (57). Vasoconstriction leads to increased total peripheral resistance and changes in cardiac output, increasing blood pressure (58). Although potentially more of a target for pharmaceutical interventions, the involvement of the sympathetic nervous system in initial stimulation of the RAAS and responsiveness to angiotensin II may provide a gateway for interventions that specifically affect the sympathetic nervous system, such as chiropractic (59-62).

Genetic bases of the regulation of the vascular resistance regulated by the autonomic nervous system

Resting blood pressure is greatly affected by genetic variability, and over 1500 genes influence the blood pressure. Several studies have explored the impact of different SNPs on the variability of blood pressure and heart rate within each individual. Genetic factors are estimated to contribute for almost 30-50% of the resting blood pressure levels (63). Similarly, twin studies showed that systolic and diastolic blood pressure levels have an heritability of 50-60%, and monozygotic twins have higher heritability than the dizygotic twins. Furthermore, blood pressure concordance is higher among biological siblings than in the adopted ones that live in the same environment. Finally, hypertension shows population-specificity in the interactions between gene and environment (12). The genetic polymorphisms associated with hypertension are found in genes involved in the following mechanisms: catecholaminergic metabolic and signaling pathways, ANS activity regulation, and baroreflex (Table 1).

Catecholaminergic signaling pathways

Most of the genes involved in hypertension participate in the catecholaminergic metabolic and signaling pathways. In a study performed by Krushkal et al., the region containing ADRB2 gene is associated with the systolic blood pressure in young Caucasians. In subsequent studies, it was found that two polymorphisms (Gln27Glu and Arg16Gly) in ADRB2 influence the inter-individual blood pressure variability and the onset of hypertension (13).

Another adrenergic receptor encoded by the gene ADR1A has several polymorphisms that show association with blood pressure in Brazilian, Caucasian and African-American populations (64). One of these polymorphisms is the Arg347Cys with the Cys/Cys genotype that is associated with hypertension (64).
The adrenergic transporter encoded by the gene \textit{SLC6A2} has a wide distribution along the nervous system, specifically in neuronal plasma membranes of noradrenergic neurons. \textit{SLC6A2} gene plays a significant role in the re-uptake of adrenalin and noradrenalin. The SNP rs168924 has been found associated with essential hypertension (65).

The \textit{TH} gene encodes the tyrosine hydroxylase, a rate-limiting enzyme that contributes in tyrosine conversion to dopamine and that plays an important role in the physiology of the adrenergic neurons. A study performed on a large general population sample proposed a relationship between the SNP rs10770141 near the \textit{TH} promoter region and blood pressure (66). Two polymorphisms of \textit{DBH}, -970C>T and -2073C>T, are associated with essential hypertension (69).

Comparative genomics analyses have identified a gene locus that might be associated with blood pressure regulation in stroke-prone spontaneously hypertensive rats corresponding to the \textit{PNMT} gene in human (70). \textit{PNMT} gene encodes phenylethanolamine N-methyltransferase enzyme which methylates the norepinephrine in order to form epinephrine, during the last step in the biosynthetic pathway of catecholamine. According to further studies in the promoter region of \textit{PNMT} two SNPs rs3764351 and rs876493 were genotyped, within three ethnic populations including White Americans, African American and Greek white population, and their results proposed that in some populations the genetic variants of

| Table 1. Genetic polymorphisms associated with hypertension |
|-------------------------------|-------------|----------------|------------------|
| Gene | Polymorphisms | Association with HT | Reference |
| \textit{TH} | rs6356, rs10770141, (TCAT), | Sympathetic function, blood pressure | 68 |
| \textit{BDKRB2} | -58C>T, rs1799722 | Baroreflex sensitivity in never-treated hypertensive patients | 76 |
| \textit{GNB3} | 825C>T, 1429C>T, 5177G>A | Increased intracellular signal transduction, essential hypertension | 72 |
| \textit{ADRB2} | Arg16Gly, Gln27Glu | Arterial blood pressure | 72 |
| \textit{ADRA1A} | Arg347Cys | Essential hypertension | 72 |
| \textit{SLC6A2} | rs168924 | Essential hypertension | 72 |
| \textit{GNAS} | 393T>C, FokI(+-/+) | Hypertension through dysfunctions of the ANS | 74 |
| \textit{AGT} | M235T | Interaction with the ANS in the regulation of blood pressure and cardiovascular function | 50 |
| \textit{AGTR1} | A1166C | Interaction with the ANS in the regulation of blood pressure and cardiovascular function | 50 |
| \textit{AGTR2} | A1675G | Interaction with the ANS in the regulation of blood pressure and cardiovascular function | 50 |
| \textit{TRPV1} | rs222747 | Contribution to BP differences during static exercise | 12 |
| \textit{GCH1} | +243C>T | Diastolic and systolic blood pressure | 73 |
| \textit{DBH} | -970C>T, -1021C>T, -2073C>T | Essential hypertension | 69 |
| \textit{PNMT} | rs876493, rs3764351 | Blood pressure regulation | 71 |
| \textit{COMT} | -1187G>C, rs4680 | Essential hypertension | 72 |
**PNMT** gene might contribute in essential hypertension onset. Furthermore a research performed in Han Chinese population confirmed that the AA haplotype of SNPs rs3764351 and rs876493 have a protective effect in that population (71).

**COMT** gene encodes the catechol-O-methyltransferase enzyme, which is an important enzyme involved in norepinephrine metabolism that plays a key role in the norepinephrine plasma levels regulation. The SNP -1187G>C is associated with essential hypertension in Japanese men, while the SNP rs4680 is associated with hypertension in Swedish and Norwegian men (72).

The **GCH1** gene encodes the GTP cyclohydrolase 1 enzyme. This enzyme is involved in the biosynthesis of two central components of the pathophysiology of hypertension, catecholamines and nitric oxide. In particular, the SNP +243C>T influences the diastolic and systolic blood pressure in females (73).

**ANS activity regulation**

Among several molecular pathways ANS is regulated by G protein-coupled receptor pathways. G proteins are a family of proteins involved in transmitting signals from a variety of external stimuli. G proteins function as heterotrimers located within the cells and are activated by G protein-coupled receptors that span through the cell membrane. G protein-coupled receptor and G proteins work together for the transmission of signals from hormones, neurotransmitters, and other signaling factors. Functional variations in these G proteins are associated with variation of ANS.

The **GNAS** gene encodes the Gα-subunit that is associated with the activity of ANS. The **GNAS** gene polymorphism T393C is associated with hypertension, and it might be a used as a genetic marker for the prediction of the onset of hypertension (74). Another common silent polymorphism, that causes the loss of a restriction site (FokI+/-) has been found associated with hypertension and with the response to the beta-blockers for the reduction of blood pressure (72).

**Baroreflex**

Sympathetic nervous system activation is fundamental for maintaining blood pressure to normal levels and the functional differences in the muscle metaboreceptors chemical sensitivity could regulate the afferent feedback to the brainstem regions that control the efferent sympathetic and parasympathetic outflow which ultimately regulates blood pressure.

Bradykinin receptor B2 (**BDKRB2**) gene encodes the G-protein coupled receptors for bradykinin protein. Bradykinin protein performs several functions including stimulation of smooth muscle spasm and vasodilation. In a study including 129 mild and moderate hypertensive patients never treated, the association of BDKRB2 gene polymorphic variant -58T>C has been reported for the autonomic-regulated baroreflex sensitivity (76).

Another research study including 200 healthy women and men disclosed that the variant in **BDKRB2**, rs1799722, together with the variant in the vanilloid receptor gene, **TRPV1**, rs222747, contribute in additive manner to the differences in blood pressure during static exercise (12).

**Activation of sympathetic and parasympathetic systems through chiropractic care**

Research studies on the effects of spinal manipulative therapy suggest that chiropractic care may influence the autonomic nervous system (24,25,77). Outcomes such as heart rate variability (HRV) and skin conductance have been shown to change following a chiropractic adjustment or osteopathic manipulation (24,25,78). HRV, an evaluation of consecutive beat-to-beat intervals of the heart, is a surrogate for extrinsic control of the heart through the ANS (24).

A systematic review by Borges et al. that examined the osteopathic and chiropractic literature found that spinal manipulation of the cervical and lumbar regions tended to illicit a greater parasympathetic response,
whereas manipulation of the thoracic regions tended towards sympathetic activation as assessed by HRV (24). This makes sense in light of the location of the anatomic pathways of the nerves for the ANS.

The parasympathetic nervous system originates from brainstem nuclei and the sacral spinal cord. The brainstem preganglionic parasympathetic fibers exit through the following cranial nerves: oculomotor (III), facial (VII), glossopharyngeal (IX), and vagus (X) (79-81). Sacral preganglionic parasympathetic fibers leave the spinal cord from sacral nerves 2, 3, and 4, joining to form the pelvic splanchnic nerves (80,81). Although the cranial nerves and sacral fibers have multiple functions within the body, of relevance to the present article are the afferent and efferent control mechanisms for heart rate and the sympathetic inhibition (6,9,80,81). Although a mechanism of action to account for the autonomic changes following a chiropractic adjustment has yet to be fully developed, the anatomic proximity of the parasympathetic nerve fibers to the cervical and sacral spinal segments and the location-based HRV changes further support a location-dependent autonomic response (25,79-81).

In contrast to the parasympathetic nervous system, pre-ganglionic sympathetic neurons with cell bodies in the lateral horn of the spinal cord exit anteriorly and enter the anterior rami of T1-L2 spinal nerves (80,82,83). Some preganglionic nerves synapse with postganglionic neurons in a series of paravertebral ganglion (sympathetic chain ganglia) that span the entire spinal column, whereas others pass through the chain ganglia. The sympathetic nerves passing through the ganglia ascend or descend the sympathetic chain or within prevertebral ganglia, respectively (80,82,83). The sympathetic nervous system innervates nearly every tissue of the body. Relative to the cardiovascular system, the sympathetic nervous system increases the heart rate, leads to activation of the RAAS system, and influences the vascular tonic state (6,80,82,83). In addition to HRV, another non-invasive way to measure sympathetic response is through measurement of the changes in skin conductance following application of a constant low voltage (84). A research, including a review and meta-analysis by Chiu et al, has shown that skin conductance can change in response to manual therapy, suggesting an increase in sympathetic nervous system activity (78,85-87).

The increased skin conductance – indicating increased sympathetic nervous system activity – results are different from the HRV location-dependent (cervical – parasympathetic increase; thoracic – sympathetic increase) manual therapy results (24,85). In alignment with the HRV results, thoracic stimulation through manual therapy indicated an increased sympathetic response; however, manual therapy to the cervical spine also indicated increased sympathetic response, contrary to the decrease observed in HRV (85). This complicates the logical anatomic relationship results shown with HRV and could be a result of the types of administered manual therapy, specific cervical vertebrae receiving manipulation, and complexity of the ascending and descending sympathetic nerve fibers. For example, in the Vicenzino study showing increased skin conductance, the therapeutic intervention was an oscillatory, lateral glide mobilization of the C5/C6 vertebrae (86). Whereas in the Welch et al. study showing increased parasympathetic response using HRV, an unspecified cervical adjustment was made in the supine position using the diversified technique (62). The diversified technique is often associated with a high-velocity low amplitude thrust (62). This inconsistency in force location and application may contribute to the inconsistent results observed in location dependent autonomic responsiveness between HRV and electrodermal responses. The inconsistency of outcome responses related to the adjusted spinal region is mirrored in the chiropractic blood pressure literature (26-29). These variations underscore the complexity of the blood pressure control mechanisms and the need for more research to understand the impact on autonomic control and the effects of presenting participant phenotypic and genotypic characteristics.

Methods and results

Chiropractic therapeutic application for hypertension

To assess the effects of chiropractic on the management of hypertension we searched articles pub-
lished from 1980 to 2019 and found 37 original studies that analyzed the effect of chiropractic therapy on hypertension (Supplementary Table 1) (23,28,29,62,88-120). The articles were pulled from PubMed, the Index to Chiropractic Literature and CINAHL, using the keywords: chiropractic, spinal manipulation, hypertension, and blood pressure. Of these studies, 10 were case reports; the statistical significance of the effects of chiropractic on blood pressure were not evaluated on these articles. Of the remaining 27, 13 did not report any significant changes in blood pressure and 14 studies showed significant changes in blood pressure after chiropractic intervention (23,28,29,62,88, 0-92, 94,95,97,99,100, 04,105,107–112,115–120). The cohorts of these 27 studies ranged from 11 to 331 individuals. Spinal manipulations were applied to the cervical spine in 16 of the 27 studies (23,28,29,62,88,90–92,94,95,97,99,100,104,105,107–112,115–120). Ten of the studies showed significant changes in blood pressure following spinal adjustments, with 6 showing no significant differences or trends only (28,62,88,90–92,94,95,100,104,105,107–112,115–120). This difference in results could be attributed to many factors. For example, several of the significant results were observed through use of specific, low force upper cervical techniques such as Atlas Orthogonality or NUCCA (28,62,88,90–92,94,95,100,104,105,107–110–112,119). While the Toggle study by Goertz et al. - not showing a significant difference in BP - also focused on the C1 or C2 vertebrae, this technique included a drop of the headpiece that the participant rested their head on for application of the adjustment (107). This could have had implications relative to local or regional nervous system effects. The results of the cervical BP studies are in alignment with the HRV research showing changes in the parasympathetic nervous system activity following cervical manipulations; however, the results are contrary to the skin conductance autonomic research which showed sympathetic stimulation following cervical manipulation (24,78,85–87).

The 6 studies evaluating blood pressure changes with thoracic manipulations exhibited contradictory results relative to benefits of thoracic spinal manipulations on BP (23,62,99,117,118). The two studies demonstrating a decrease in BP following chiropractic care were in hypertensive patients and both utilized instrument adjusting (23,99). Only one of the three studies showing no significant difference included hypertensive patients; the two other study participant groups were non-hypertensive (62,117,118). All studies showing no change in BP utilized manual manipulative procedures (62,117,118). Interestingly, none of the thoracic BP studies showed an increase in BP, which would be expected based on the sympathetic nervous system and spinal manipulation research (24,25,78,85–87). Both HRV and electrodermal responses showed elevated sympathetic activity following a thoracic adjustment, basic physiology would suggest that the elevated sympathetic response would increase blood pressure (6,24,25,78,85–87). This increase was not reflected in the BP and manual therapy literature, excepting a small study by Wickles that showed slightly elevated BP in the ankle (23,62,99,115,117,118).

Finally, the full-spine and lumbar manipulation and BP literature showed mixed results similar to the thoracic manipulation results (29,97,108–110,115,116). The one lumbar only manipulation study by Younes, which employed osteopathic HVLA thrusts, mobilization, and muscle work, did not show a significant difference in blood pressure (116); however, the care did show a significant response to parasympathetic responsiveness through evaluation of the baroreceptor response (116). Of the research studies utilizing a full-spine approach, three showed changes in blood pressure and three did not (29,97,108,109,116,120). This could be related to several factors. For example, application of force at multiple different sites could have triggered both parasympathetic and sympathetic systems, complicating physiologic responsiveness. Additionally, the types of manipulative techniques varied from osteopathic manipulation and Gonstead chiropractic in the no significant change studies to chiropractic diversified adjustments and the McTimoney chiropractic method in studies demonstrating significant changes post care (29,97,108,109,116,120).

The variation in results and methodologies employed in the research of spinal manipulative therapy for blood pressure limit any conclusions that could be made relative to chiropractic or other manual therapy techniques and the effect on blood pressure. This suggests that more research is needed. The research utilizing adjustments to the cervical spine more consistently
demonstrate decreases in BP following manipulative therapy (28,62,88,90-92,94,95,100,104,105,107,110-112,119). The anatomic, HRV and electrodermal literature seem to support the cervical spine as an intervention point to influence the autonomic nervous system, although the electrodermal research seems counter to the HRV literature relative to which autonomic system is activated (24,25,77,78,85-87). One cervical manipulation and HRV study by Budgell et al. does show an increase in low frequency response, which is often attributed to sympathetic activation; however, increased sympathetic activation would suggest a blood pressure increase (121). This further illustrates the complexity of the intervention-response research and may indicate the need for improved understanding of the underlying neurophysiology related to BP control, location dependent nervous system responses to manipulative therapy, and participant characteristics prior to study onset.

Discussion and conclusions

Hypertension is a multifactorial disease, strongly dependent on the responsiveness of the ANS (6,30). This responsiveness depends on the integrity of the afferent and efferent pathways, sensory end organ reactivity, and interactions with systems such as renal and cardiovascular (6,9-11). These interactions produce short- and long-term adaptations to changes in the internal and external environment, creating complex feedback loops such as the baroreceptor reflex and the RAAS (6,9-11,32,42,43,50). Further, individual genetic predisposition also provides a complicating layer to the control of hypertension (63). Given the complexity of BP control, it is not surprising that pharmacotherapy, the primary mechanism for controlling blood pressure, has a 20-30% incidence of resistant hypertension (15,19,20).

The aim of this article was to summarize some of the physiologic and genetic bases of hypertension and review the chiropractic and manual therapy literature related to autonomic regulation and blood pressure control. This may provide a starting point for examining the efficacy of chiropractic as a therapeutic intervention to fill the gap in the need for treatment of hypertension, especially resistant hypertension, and could inform future study design in this area.

The results of the present review were mixed. While the research examining manual therapy to the cervical spine were the most supportive of chiropractic care as an intervention to lower blood pressure, evaluation of the ANS responses to cervical manipulation were only supportive in the HRV literature (24,25,77,78). The inconclusiveness related to manual therapy as a proposed intervention for blood pressure regulation has also been supported in other literature reviews (26,27,122). A review by Mangum and colleagues suggests that more low bias research is needed in order to draw conclusions relative to the effectiveness of chiropractic care for the hypertensive patient (27). As part of the UK Evidence Report and an evaluation of the effect of chiropractic treatment on primary and early secondary prevention of disease, reviews by Bronfort et al and Goncalves et al, respectively, further suggested a lack of evidence in support of chiropractic as a suggested care modality for hypertension (27,122).

While the aim of the present article was to provide a multi-perspective overview of hypertension and blood pressure regulation, the review was limited by the lack of a formal grading system for the blood pressure and autonomic literature. However, the less rigorous nature does provide an expanded perspective that raises more questions about the need for additional research. Some studies used normotensive patients, others used hypertensive patients at varying levels of hypertension, and others had a too small sample size to draw definite conclusions. Further, many studies utilized students as a convenience sample, which may be a challenge due to the stress induced by academics. Previous research also did not take into account genetic predisposition. Individual genetic background can have effects on regulation of the sympathetic and parasympathetic tone, which could impact the responses to chiropractic therapy (63). One example is the GNAS gene, encoding the Gs-protein -subunit, associated with the activity of ANS and its polymorphism T393C, associated with hypertension (74). Additionally, studies examining the effects of chiropractic care on ANS activity demonstrated inconsistencies related to HRV, electrodermal responses, and predicted blood pressure responses (42,43,50). This illustrates
the complexity of therapeutic intervention development and study of hypertension.

Uniquely, this overview provided a brief introduction to some of the complex physiologic and genetic factors that comprise the multifactorial control of blood pressure and regulation of hypertension. The results of the review of manual therapy literature related to ANS responses and blood pressure were promising, but often contradictory. In some cases, although the lowering of BP was statistically significant, it was not clinically significant, in other cases the effect was short-term. This suggests that more research should be done and that consideration of the complexity of ANS control and patient presenting physiologic and genetic characteristics would be valuable. With further research, these presenting characteristics may help to serve as a predictor for patient blood pressure responsiveness to chiropractic care.

Conflict of interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

References

1. Petkovich BW, Vega J, Thomas S. Vagal modulation of hypertension. Curr Hypertens Rep 2015; 17: 532.
2. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD), US: National Heart, Lung, and Blood Institute, 2004: 04-5230.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217-23.
4. Dickson ME, Sigmund CD. Genetic basis of hypertension: Revisiting angiotensinogen. Hypertension 2006; 48: 14-20.
5. Bolivar JJ. Essential hypertension: An approach to its etiology and neurogenic pathophysiology. Int J Hypertens 2013; 2013: 547809.
6. Grassi G. Sympathetic neural activity in essential hypertension and its correlates: Systematic reviews and meta-analyses. Hypertension 2018; 72: 483-91.
7. Grassi G, Seravalle G, Quarti-Trevano F. The “neuroadrenergic hypothesis” in hypertension: Current evidence. Exp Physiol 2010; 95: 581-6.
8. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res 2015; 116: 976-90.
9. Notay K, Klingel SL, Lee JB, et al. TRPV1 and BDKRB2 receptor polymorphisms can influence the exercise pressor reflex. J Physiol 2018; 596: 5135-48.
10. Krushkal J, Ferrell R, Mockrin SC, Turner ST, Sing CF, Borrowe E. Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings. Circulation 1999; 99: 1407-10.
11. Grassi G, Ram VS. Evidence for a critical role of the sympathetic nervous system in hypertension. J Am Soc Hypertens 2016; 10: 457-66.
12. Braam B, Talor SJ, Rahman M, et al. Recognition and management of resistant hypertension. Clin J Am Soc Nephrol 2017; 12: 524-35.
13. Handle A, Lloyd E, Roberts A, Barger R. Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: A one-year, phase 3, open-label study. Clin Exp Hypertens 2016; 38: 180-8.
14. Jung HW, Kim KI, Park CG, et al. A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study). Clin Exp Hypertens 2015; 37: 482-9.
15. Rakugi H, Tsujihiashi T, Shimada K, et al. Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. Clin Exp Hypertens 2015; 37: 260-6.
16. Doroszko A, Janus A, Szahidewicz-Krupska E, Mazur G, Derkacz A. Resistant hypertension. Adv Clin Exp Med 2016; 25: 173-83.
17. Calhoun D, Schiffrin E, Flack J. Resistant hypertension: An update. Am J Hypertens 2019; 32: 1-3.
18. Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E. Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension 2014; 64: 501-7.
19. Yaxley J, Thambir. Resistant hypertension: An approach to management in primary care. J Fam Med Prim Care 2015; 4: 193-9.
20. Yates RG, Lamping DL, Abram NL, Wright C. Effects of chiropractic treatment on blood pressure and anxiety: A randomized, controlled trial. J Manipulative Physiol Ther 1988; 11: 484-8.
21. Amoroso Borges BL, Bortolazzo GL, Neto HP. Effects of spinal manipulation myofascial techniques on heart rate variability: A systematic review. J Bodyw Mov Ther 2018; 22: 203-8.
22. Bolton PS, Budgell B. Visceral responses to spinal manipulation. J Electromyogr Kinesiol 2012; 22: 777-84.
Chiropractic and hypertension

26. Bronfort G, Haas M, Evans R, Leininger B, Triano J. Effectiveness of manual therapies: The UK evidence report. Chiropr & Osteopat 2010; 18: 3.

27. Mangum K, Partna L, Vavrek D. Spinal manipulation for the treatment of hypertension: A systematic qualitative literature review. J Manipulative Physiol Ther 2012; 35: 235-43.

28. McKnight ME, DeBoer KF. Preliminary study of blood pressure changes in normotensive subjects undergoing chiropractic care. J Manipulative Physiol Ther 1988; 11: 261-6.

29. McMasters KL, Wang J, York J, Hart J, Neely C, Delain RJ. Blood pressure changes in African American patients receiving chiropractic care in a teaching clinic: A preliminary study. J Chiropr Med 2013; 12: 55-9.

30. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res 2014; 114: 1804-14.

31. Armstrong M, Moore RA. Physiology, baroreceptors. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2019.

32. Fountain JH, Lappin SL. Physiology, renin angiotensin system. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2018.

33. Patil SJ, Wareg NK, Hodges KL, Smith JB, Kaiser MS, LeFevre ML. Home blood pressure monitoring in cases of clinical uncertainty to differentiate appropriate inaction from therapeutic inertia. Ann Fam Med 2020; 18: 50-8.

34. Schnaubelt S, Hammer A, Koller L, et al. Expert opinion: Meditation and cardiovascular health: What is the link? Eur Cardiol 2019; 14: 161-14.

35. Mancia G. Short- and long-term blood pressure variability: Present and future. Hypertension 2012; 60: 512-7.

36. Mark AL. The sympathetic nervous system in hypertension: A potential long-term regulator of arterial pressure. J Hypertens Suppl 1996; 14: S159-65.

37. Grassi G, Pisano A, Bolignano D, et al. Sympathetic nerve traffic activation in essential hypertension and its correlates: systematic reviews and meta-analyses. Hypertension 2018; 72: 483-91.

38. Oparil S, Acelajado MC, Bakris GL, et al. Hypertension. J Am Soc Nephrol 2014; 25: 1776-802.

39. Julius S. Autonomic nervous system dysregulation in human hypertension. Am J Cardiol 1991; 67: 3B-7B.

40. Ernst G. Heart-rate variability—More than heart beats? Front Public Heal 2017; 5: 240.

41. Fisher JP, Paton JFR. The sympathetic nervous system and blood pressure in humans: Implications for hypertension. J Hum Hypertens 2012; 26: 463-75.

42. Albaghdadi M. Baroreflex control of long-term arterial pressure. Rev Bras Hipertens 2007; 14: 212-25.

43. Jordan J, Biaggioni I. Genetic influences on human baroreflex regulation. Auton Neurosci Basic Clin 2012; 172: 23-5.

44. Shahoud J, Acedula NR. Physiology, arterial pressure regulation. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2019.

45. Andani R, Khan YS. Anatomy, head and neck, carotid sinus. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2020.

46. Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM. The diagnosis and treatment of baroreflex failure. N Engl J Med 1993; 329: 1449-55.

47. Smit AAJ, Halliwill JR, Low PA, Wieling W. Pathophysiological basis of orthostatic hypotension in autonomic failure. J Physiol 1999; 519: 1-10.

48. Hirooka Y. Importance of neural arc for baroreflex resetting in hypertension. Circ J 2015; 79: 510-2.

49. Hirooka Y, Kishi T, Ito K, Sunagawa K. Potential clinical application of recently discovered brain mechanisms involved in hypertension. Hypertension 2013; 62: 995-1002.

50. Nishikino M, Matsunaga T, Yasuda K, et al. Genetic variation in the renin-angiotensin system and autonomic nervous system function in young healthy Japanese subjects. J Clin Endocrinol Metab 2006; 91: 4676-81.

51. MacFadyen RJ, Lees KR, Reid JL. Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol 1991; 31: 1-13.

52. Lees KR, MacFadyen RJ, Reid JL. Tissue angiotensin converting enzyme inhibition: relevant to clinical practice? Am J Hypertens 1990; 3: 2665-72S.

53. Macfadyen RJ, Lees KR, Reid JL. Perindopril. A review of its pharmacokinetics and clinical pharmacology. Drugs 1990; 39: 49-63.

54. Said SI. Metabolic functions of the pulmonary circulation. Circ Res 1982; 50: 325-33.

55. Scott JH, Dunn RJ. Physiology, aldosterone. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2019.

56. McKinley MJ, McAllen RM, Pennington GL, Smedrinas A, Weisinger RS, Oldfield BJ. Physiological actions of angiotensin II mediated by AT1 and AT2 receptors in the brain. Clin Exp Pharmacol Physiol 1996; 23: S99-104.

57. Warren JH, Lewis W, Wraa CE, Stebbins CL. Central and peripheral effects of angiotensin II on the cardiovascular response to exercise. J Cardiovasc Pharmacol 2001; 38: 693-705.

58. Delong C, Sharma S. Physiology, peripheral vascular resistance. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2019.

59. Okamura K, Yano Y, Takamiya Y, Shirai K, Urata H. Efficacy and safety of a combination antihypertensive drug (olmesartan plus azelnidipine): “Issues with hypertension studies in real-world practice.” Clin Exp Hypertens 2019: 1-11.

60. LiverTox: Clinical and Research Information on Drug-induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2018.

61. Llorens-Cortes C, Touyz RM. Evolution of a new class of antihypertensive drugs: targeting the brain renin-angiotensin system. Hypertens (Dallas, Tex 1979) 2020; 75: 6-15.

62. Welch A, Boone R. Sympathetic and parasympathetic responses to specific diversified adjustments to chiropractic vertebral subluxations of the cervical and thoracic spine. J Chiropr Med 2008; 7: 86-93.

63. Xu X, Ding X, Zhang X, et al. Genetic and environmental influences on blood pressure variability: A study in twins. J Hypertens 2013; 31: 690-7.

64. Freitas SR, Pereira AC, Floreano MS, Mill JG, Krieger JE. Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population. BMC Cardiovasc Disord 2008; 8: 40.
65. Chitbangonsyn SW, Mahboubi P, Walker D, et al. Physical mapping of autonomic/sympathetic candidate genetic loci for hypertension in the human genome: A somatic cell radiation hybrid library approach. J Hum Hypertens 2003; 17: 319-24.
66. Abe M, Wu Z, Yamamoto M, et al. Association of dopamine β-hydroxylase polymorphism with hypertension through interaction with fasting plasma glucose in Japanese. Hypertens Res 2005; 28: 215-21.
67. Rao F, Zhang L, Wessel J, et al. Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: Discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivo. Circulation 2007; 116: 993-1006.
68. Rao F, Zhang L, Wessel J, et al. Adrenergic polymorphism and the human stress response. Ann NY Acad Sci 2008; 1148: 282-96.
69. Chen Y, Zhang K, Wen G, et al. Human dopamine β-hydroxylase promoter variant alters transcription in chromaffin cells, enzyme secretion, and blood pressure. Am J Hypertens 2011; 24: 24-32.
70. Jacob JJ, Lindpaintner K, Lincoln SE, et al. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell 1991; 67: 213-24.
71. Huang C, Zhang S, Hu K, Ma Q, Yang T. Phenylethanolamine N-methyltransferase gene promoter haplotypes and risk of essential hypertension. Am J Hypertens 2011; 24: 1222-6.
72. Bojic T, Milovanovic B, Cupic SJ. Genetic polymorphisms of neurocardiovascular disorders. Arch Med 2015; 7: 1-22.
73. Zhang L, Rao F, Zhang K, et al. Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J Clin Invest 2007; 117: 2658-71.
74. Yasuda K, Matsunaga T, Moritani T, et al. T393C polymorphism of GNAS1 associated with the autonomic nervous system in young, healthy Japanese subjects. Clin Exp Pharmacol Physiol 2004; 31: 597-601.
75. Cabadak H, Orun O, Nacar C, et al. The role of G protein α3 subunit polymorphisms C825T, C1429T, and G5177A through interaction with fasting plasma glucose in Japanese hypertensive patients. J Hypertens 2011; 29: 255-74.
76. Chitbangonsyn SW, Mahboubi P, Verheijden S, Boeckxstaens GE. The vagus nerve in appetite regulation, mood, and intestinal inflammation. Gastroenterology 2017; 152: 730-44.
77. Waxenbaum JA, Varacallo M. Anatomy, autonomic nervous system. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2020.
80. Tindle J, Tadi P. Neuroanatomy, parasympathetic nervous system. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2020.
practic adjustments and brief massage treatment at sites of subluxation in subjects with essential hypertension: Pilot study. J Manipulative Physiol Ther 2002; 25: 221-39.
98. Prater-Manor S, Clifton E, York A. Resolution of anxiety and hypertension in a 60-year old male following subluxation based chiropractic care: A case study and review of the literature. Ann Vert Sublux Res 2015: 146-53.
99. Roffers S, Huber L, Morris D, Stiles A, Barton D, House T. A randomized controlled trial to measure the effects of specific thoracic chiropractic adjustments on blood pressure and pulse rate. Clin Chiropr 2011; 14: 169-70.
100. Roffers S, Stiles A, Huber L, Morris D, Barton D, House T. Measuring the effects of specific cervical chiropractic adjustments on blood pressure and pulse rate: A randomized controlled trial. Clin Chiropr 2011; 4: 170.
101. Qualls T, Lester C. Resolution of atrial fibrillation & hypertension in a patient undergoing upper-cervical chiropractic care. J Upper Cervical Chiropr Res 2012: 9-15.
102. Whedon E. Upper cervical specific chiropractic management of a patient with hypertension: A case report and selective review of the literature. J Upper Cervical Chiropr Res 2013: 1-13.
103. Kessinger R, Moe C. Improvement in chronic hypertension following a single upper cervical adjustment: A case report. J Upper Cervical Chiropr Ther 2015: 1-5.
104. Schwartzbauer J, Kolber J, Schwartzbauer M, Hart J, Zhang J. Athletic performance and physiological measures in baseball players following upper cervical chiropractic care: A pilot study. J Vert Sublux Res 1997; 1: 1.
105. Scott RM, Kaufman CL, Dengel DR. The impact of chiropractic adjustments on intracranial blood flow: A pilot study. J Vert Sublux Res 2007: 1-8.
106. Chung J, Brown J, Busa J. Resolution of hypertension following reduction of upper cervical vertebral subluxation: A case study. J Upr Cerv Chiropr Res 2014; 1: 1-6.
107. Goertz CM, Salsbury SA, Vining RD, et al. Effect of spinal manipulation of upper cervical vertebrae on blood pressure: results of a pilot sham-controlled trial. J Manipulative Physiol Ther 2016; 39: 369-80.
108. Goertz CH, Grimm RH, Svendsen K, Grandits G. Treatment of hypertension with alternative therapies (THAT) study: A randomized clinical trial. J Hypertens 2002; 20: 2063-8.
109. Holt K, Beck R, Sexton S, Taylor HH. Reflex effects of a spinal adjustment on blood pressure. Chiropr Aust 2010; 40: 95.
110. Morgan JP, Dickey J, Hunt H, Hudgins P. A controlled trial of spinal manipulation in the management of hypertension. J Am Osteopath Assoc 1985; 85: 308-13.
111. Win NN, Jorgensen AMS, Chen YS, Haneline MT. Effects of upper and lower cervical spinal manipulative therapy on blood pressure and heart rate variability in volunteers and patients with neck pain: A randomized controlled, crossover, preliminary study. Chiropr Med 2015; 14: 1-9.
112. Nansel D, Jansen R, Cremata E, Dhami M, Holley D. Effects of cervical adjustments on lateral-flexion passive end-range asymmetry and on blood pressure, heart rate and plasma catecholamine levels. J Manipulative Physiol Ther 1991; 14: 450-6.
113. Van Dyke V, Russell D, Alcantar J. Resolution of hypertension in a 72-year-old male following subluxation based chiropractic care: A case report and selective review of the literature. Ann Vert Sublux Res 2015: 172-6.
114. Vansen Z. Reduction of blood pressure in a patient receiving chiropractic care: A case study & review of literature. Annals of Vert Sublux Res 2017; 2017: 15-33.
115. Wickes D. Effects of thoracolumbar spinal manipulation on arterial flow in the lower extremity. J Manipulative Physiol Ther 1980; 3: 3-6.
116. Younes M, Nowakowski K, Didier-Laurent B, Gombert M, Cottin F. Effect of spinal manipulative treatment on cardiovascular autonomic control in patients with acute low back pain. Chiropr & Manual Ther 2017; 25: 33.
117. Ward J, Coats J, Tyer K, Weigand S, Williams G. Immediate effects of anterior upper thoracic spine manipulation on cardiovascular response. J Manipulative Physiol Ther 2013; 36: 101-10.
118. Ward J, Tyer K, Coats J, Williams G, Kulcak K. Immediate effects of upper thoracic spine manipulation on hypertensive individuals. J Manipulative Physiol Ther 2015; 23: 43-50.
119. Watanabe N, Polus BI. A single mechanical impulse to the neck: Does it influence autonomic regulation of cardiovascular function? Chiropr J Aust 2007; 37: 42.
120. Dimmick KR, Young MF, Newell D. Chiropractic manipulation affects the difference between arterial systolic blood pressures on the left and right in normotensive subjects. J Manipulative Physiol Ther 2006; 29: 46-50.
121. Budgell B, Hirano F. Innocuous mechanical stimulation of the neck and alterations in heart-rate variability in healthy young adults. Auton Neurosci 2001; 91: 96-9.
122. Goncalves G, Le Scanff C, Leboeuf-Yde C. Effect of chiropractic treatment on primary or early secondary prevention: A systematic review with a pedagogic approach. Chiropr Man Ther 2018; 26: 10.

Received: 3 September 2020
Accepted: 14 October 2020
Correspondence:
Stefano Paolacci
Via delle Maioliche, 57/D, Rovereto (TN), Italy
E-mail: stefano.paolacci@assomagi.org
Table S1. Brief description of research studies investigating the effects of chiropractic therapy on hypertension

| First author, year | Participants | Study design | Control group | Type of CMT | Results | Limitations |
|--------------------|--------------|--------------|---------------|-------------|---------|-------------|
| Bakris et al 2007   | 50 patients with stage 1 hypertension subdivided in treated (25) and controls (25) | Double blind, placebo controlled. Duration: 8 weeks | Treatment vs placebo | Atlas/Upper cervical chiropractic adjustment | Systolic BP (treatment: -17+/−9 mmHg vs placebo: -3+/−11 mmHg, P<0.0001); Diastolic BP (treatment: -10+/−11 mmHg vs placebo: -2+/−7 mmHg, P=0.002). | Should be confirmed in a larger trial |
| Torns 2012         | 42 patients subdivided in 3 groups: 12 hypertensive, 12 normotensive, 18 pre-hypertensive or stage 1 or stage 2 hypertensive | Cohort study. Duration: 1 treatment | Pre-treatment vs post-treatment | Atlas orthogonal upper cervical adjustment | Hypotensive group: systolic BP (+13.83 mmHg, p<0.0001); diastolic BP (+8.83, p=0.0003). Normotensive group: systolic BP (-3.92, p=0.1107); diastolic BP (-1.58, p=0.2486). Pre-hypertensive + hypertensive groups: systolic BP: -20.22 mmHg, p<0.0001; diastolic BP: -6.83 mmHg, p<0.0001. No adverse effects recorded. | Absence of a specific control group. Follow-up measurements did not measure the duration of the effects |
| Torns 2014         | 20 participants (10 placebo group, 10 therapeutic group) | Placebo-controlled, randomized, prospective longitudinal cohort study. Duration: 6 weeks | Controls vs treatment | Atlas orthogonal upper cervical chiropractic care | Systolic BP (-12.2 mmHg, p<0.05); Diastolic BP (-7.2, p<0.05) | The effect on the diastolic values were not significant after 4 weeks |
| Ward et al 2012    | 48 normotensive college students (24 controls, 24 treated) | Single blind, randomized controlled trial. Duration: 24h | Controls vs treatment | Atlas cervical break | No significant differences before and after chiropractic care compared to head turn and no contact-control | Non-hypertensive patients |
| Knutson 2001       | 110 patients (80 in test one, 30 in test two) | Comparison study | Test 1: controlled clinical trial with a treatment group and a control group. Test 2: controlled clinical trial with subjects as controls | Vectored upper cervical care | Test 1: Significant decrease in systolic blood pressure (p<0.001); Test 2: No significant decrease in systolic blood pressure | Lack of randomization, blinding, manipulated control group |
| Kessinger et al 2019 | 130 patients subdivided in 3 groups: 54 with low pulse pressure (<40 mmHg), 29 with medium pulse pressure (40–49 mmHg), 47 with high pulse pressure (>49 mmHg) | Observational comparison study | Pre-treatment vs post-treatment | Knee chest upper cervical | Pulse pressure (-8.9 mmHg, p<0.01) in patients with hypertension | Lack of randomization, not a clinical trial |

(continued on next page)
Table S1 (continued). Brief description of research studies investigating the effects of chiropractic therapy on hypertension

| Study                        | Participants | Intervention | Comparator | Outcome | Notes |
|------------------------------|--------------|--------------|------------|---------|-------|
| Plaugher et al 2002<sup>27</sup> | Subdivided in 3 groups: 9 undertook chiropractic, 8 a brief massage, 6 untreated. Study duration: 2 months | Randomized controlled trial with 3 parallel groups. Duration: 2 months | Chiropractic group vs brief massage/untreated groups | Gonstead technique | BP decreased in all 3 groups (largest change in control group) | Small cohort |
| Roffers, Huber et al 2011<sup>99</sup> | 331 subjects subdivided in control (108), sham adjustment (117), treatment (106) | Randomized control trial. Duration: 1 treatment | Treatment vs control/placebo | Specific thoracic (TS-T1) chiropractic treatment | Systolic and diastolic BP decreased significantly (p<0.0001) in the treatment group. No significant changes in the placebo and control groups | The authors did not collect hypertensive medication history and current usage. The trial was not double-blind. Anxiety might have increased the systolic and diastolic scores before treatment |
| Roffers, Stiles et al 2011<sup>100</sup> | 331 subjects subdivided in control (108), sham adjustment (117), treatment (106) | Randomized control trial. Duration: 1 treatment | Treatment vs control/placebo | Cervical (C3 to occiput C1) chiropractic adjustment | Systolic and diastolic BP decreased significantly (p<0.0001) in the treatment group. No significant changes in the placebo and control groups | The authors did not collect hypertensive medication history and current usage. The trial was not double-blind. Anxiety might have increased the systolic and diastolic scores before treatment |
| Scott et al 2007<sup>105</sup> | 20 healthy chiropractic students subdivided in chiropractic adjustment (10), control group (10) | Randomized control trial. Duration: 1 treatment | Treatment vs control | Cervical HVLA | A single cervical adjustment had no effect on systolic or diastolic BP | No hypertensive patients, small cohort |
| Goertz et al 2016<sup>107</sup> | 51 participants with prehypertension or stage 1 hypertension. Treatment group (24), control group (27) | Randomized placebo-controlled clinical trial. Duration: 6 weeks | Treatment vs control | Toggle recoil upper cervical chiropractic | Sham group: systolic BP (-4.2 mmHg), diastolic BP (-1.6 mmHg). Treatment group: systolic BP (0.6 mmHg), diastolic BP (0.7 mmHg). The difference was not statistically significant. No serious adverse events noted | Patients in treatment group treated with antihypertensive medications were not washed out. The sham procedure was not validated for BP studies |
| Goertz et al 2002<sup>108</sup> | 140 subjects with high to normal BP or stage 1 hypertension subdivided in diet group (69) and chiropractic group (71) | Randomized double-blind controlled trial. Duration: 4 weeks | Chiropractic treatment vs diet treatment | High velocity, short-lever impulse/force applied directly to a joint space | Systolic/diastolic BP average decrease in control group (-4.9/-5.6 mmHg). Systolic/diastolic BP decrease in treated group (-3.5/-4.0 mmHg). No statistically significant changes among groups | Lack of a no treatment control group |
| Holt et al 2010<sup>109</sup> | 70 patients subdivided in treated (35) and control (35) groups | Randomized controlled clinical trial. Duration: 1 treatment | Treatment vs control | Diversified | Systolic blood pressure (-3.9 mmHg, p=0.002) | Average changes in blood pressure were not clinically significant |

(continued on next page)
### Table S1 (continued). Brief description of research studies investigating the effects of chiropractic therapy on hypertension

| Study Reference | Study Design | Sample Description | Procedure Details | Blood Pressure Changes | Notes |
|-----------------|--------------|--------------------|-------------------|------------------------|-------|
| McKnight et al 1988 | Nonrandomized controlled clinical trial. Duration: 1 treatment | 75 students undergoing routine chiropractic care (53 treated, 22 control group) | Treatment vs control Cervical adjustment via Gonstead method | Systolic BP (-2.8 mmHg, p<0.01), diastolic BP (-2.6 mmHg, p<0.01) were statistically significantly lower than the controls | Average changes in blood pressure not clinically significant |
| McMasters et al 2013 | Nonrandomized. Duration: 23 visits | 24 prehypertensive or hypertensive stage 1, with or without medication | Pre-treatment vs post-treatment Adjustments from a full spine exam | Average systolic/diastolic BPs (no statistically significant pre/post differences for pre-hypertensive patients, p>0.05). Average systolic BP (-12.8 mmHg, p=0.009), average diastolic BP (-7.6, p=0.0012) for stage 1 hypertensive patients | The patients were not randomized. No control group. High dropout rate. Lack of accounting of confounding determinants of hypertension (diet, exercise) |
| Schwartzbauer et al 1997 | Longitudinal study with control group. Duration: 14 weeks | 21 male university baseball players aged 19-23 (9 treated, 12 controls) | Treatment vs control Upper cervical | No statistically significant differences recorded for blood pressure in controls or treated subjects | Small sample size |
| Morgan et al 1985 | Randomized placebo-controlled trial. Duration 18 weeks | 29 randomly selected subjects | Treatment vs control Osteopathic spinal manipulation, occipito-atlantal and thoracolumbar | No significant difference in the BP after manipulation | Small sample size |
| Win et al 2015 | Randomized controlled, cross-over. Duration: 1 treatment | 10 asymptomatic normotensive volunteers + 10 normotensive patients with acute neck pain | Pre-treatment vs post-treatment for both groups | Upper or lower cervical, using high velocity, low amplitude Systolic BP (-11 mmHg, p<0.05) in asymptomatic normotensive volunteers. Systolic BP (-10 mmHg, p<0.05) in normotensive patients with acute neck pain | Small sample size. No control or sham group. Lack of control over variables (diet, exercise) |
| Nansen et al 1991 | Nonrandomized. Duration: 1 treatment | 24 healthy, asymptomatic, nonsmoking males (12 treated, 12 controls) | Treatment vs control Unilateral lower cervical spinal adjustment | No significant differences between adjusted and non-treated subjects in blood pressure | Small sample size, non-hypertensive subjects |
| Welch et al 2008 | Randomized trial. Duration: 1 treatment | 40 patients of 21-55 years old, non-hypertensive, no history of heart disease | Pre-treatment vs post-treatment | Diversified cervical segment adjustment or a diversified thoracic segment adjustment Diastolic BP (-5.6 mmHg, p=0.038) only after cervical adjustments. No significant reductions for thoracic adjustments | Non-hypertensive patients |
| Wickes 1980 | Double-blind. Duration: 1 treatment | 20 normotensive individuals | Pre-treatment vs post-treatment Thoracolumbar spinal manipulation | Systolic BP (+4.0 mmHg) 5 minutes post-manipulation | Non-hypertensive patients |
| Yates et al 1988 | Randomized placebo-controlled trial. Duration: 1 treatment | 21 hypertensive patients (7 treatment, 7 placebo, 7 no treatment) | Treatment vs placebo/control Adjusting instrument to thoracic spine (Activator) | Systolic and diastolic blood pressure decreased significantly in the active treatment condition | Small sample size |
| Younes et al 2017 | Randomized placebo-controlled trial. Duration: 1 week | 17 patients with acute back pain (10 treatment, 7 placebo) | Treatment vs placebo | Osteopathic spinal manipulation therapy No significant differences in the blood pressure | Small sample size, non-hypertensive patients |

(continued on next page)
| Study                  | Participants | Design                               | Treatment vs Control | Intervention                                                                 | Findings                                                                                     |
|------------------------|--------------|---------------------------------------|----------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Ward et al 2013        | 36 students  | 3-arm randomized single-blind controlled trial, Duration: 1 treatment | Treatment vs placebo/control | Anterior thoracic manipulation of T1-4                                       | No statistically significant or clinically relevant difference was shown amongst any between-group or within-group cardiovascular dependent variables |
| Ward et al 2015        | 50 hypertensive patients | Single blind, controlled trial, Duration: 1 treatment | Treatment vs control | Upper thoracic spinal manipulative therapy                                     | Short-term cardiovascular physiology is not affected by upper thoracic spine SMT in hypertensive individuals to a clinically relevant level |
| Watanabe et al 2007    | 11 young healthy adults | Pre/post test comparison, Duration: 1 treatment | Pre-treatment vs post-treatment | Mechanically stimulate cervical manipulation                                   | Significant reductions in BP after application of the mechanical stimulus in the supine posture (p<0.05). The reduction peaked at 20 seconds post-stimulation. |
| Dimmick et al 2006     | 70 Patients (35 treatment, 35 control) | Nonrandomized, matched pair, controlled clinical trial | Treatment vs control | McTimoney technique of chiropractic manipulation                              | No significant difference between controls and treatment group                                                                 |

Table S1 (continued). Brief description of research studies investigating the effects of chiropractic therapy on hypertension.